Technology-enabled specialty pharmacy utilization of the routine assessment of patient index data 3 (RAPID3) to monitor and enhance outcomes of rheumatoid arthritis (RA) patients – a retrospective review
Background: Rheumatoid arthritis is a chronic progressive autoimmune disease affecting 1.5 million people in the United States. Uncontrolled disease can lead to irreversible joint damage, deformity, and disability. Current practice guidelines by the American College of Rheumatology (ACR) recommend frequent monitoring of disease activity and treatment to a goal of remission or low severity. However, clinicians’ adherence to this treatment strategy is low. With monthly patient contact, specialty pharmacies are well positioned to facilitate patient outcomes tracking. The RAPID3 is a validated quality measure instrument endorsed by the ACR to monitor patient disease activity. TherigySTM is a therapy management software utilized by pharmacies to deliver and document specialty therapy management. The availability of RAPID3 implemented in TherigySTM® demonstrates the opportunity for pharmacies to optimize patient care. Objectives: To observe the potential of technology-enabled delivery and utilization of RAPID3 to RA patients by specialty pharmacies to augment patient care and better comply with guidelines. Methods:• TherigySTM® generated RAPID3 initial and auto-triggered follow-up assessments based on the previous score per guideline recommendations.• TherigySTM® prompted engagement of patients by pharmacists to conduct RAPID3 surveys.• Captured aggregated data for 944 unique patients managed between 12/1/17 and 8/5/18 by selected specialty pharmacies using TherigySTM® with more than 50 completed RAPID3 assessments.• RAPID3 score calculated to non-simplified scale of 0–30. • Potential trends and metrics were identified with data captured. Results: 85% of follow-up RAPID3 assessments scheduled via TherigySTM® were completed on time. Initial RA disease activity assessments were able to be stratified: 47% high, 28% moderate, 15% low and 10% Remission. Ongoing disease activity changes were trackable and monitored by pharmacists over the course of therapy (55% of observed patients had no change, 31% improved and 14% worsened). 265 patients with moderate to high disease activity completed follow-up RAPID3 assessments. The average patient received 1–2 follow-up assessments during the observation period. Conclusions: Technology-enabled clinical support has the potential to improve compliance with practice guidelines. Pharmacies using validated instruments such as the RAPID3 delivered via TherigySTM® can expand their role in monitoring and enhancing outcomes. In a multi-disciplinary setting, pharmacy can efficiently share outcomes data with providers and make appropriate recommendations.